skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Denileukin Diftitox (Code C1476)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Denileukin Diftitox

Definition: A cytotoxic recombinant protein consisting of interleukin-2 (IL-2) protein sequences fused to diphtheria toxin. The IL-2 protein sequence moiety of denileukin difitox directs the cytocidal action of diphtheria toxin to cells that express IL-2 receptors. After the toxin moiety is internalized into target IL-2 receptor-expressing cells, its catalytic domain catalyzes the transfer of the ADP-ribose moiety of NAD to a posttranslationally modified histidine residue of elongation factor 2 (EF-2), called diphthamine. This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in cell death. (NCI04)

NCI-GLOSS Definition: A drug used to treat cutaneous T-cell lymphoma that can bind the cytokine IL-2 and that has not responded to other treatment. It is also being studied in the treatment of other types of cancer. Ontak is made by combining a part of IL-2 with a bacterial toxin. The IL-2 part of the drug attaches to the cancer cells and then the toxin kills the cells. Ontak is a type of immunotoxin and a type of fusion toxin.

Display Name: Denileukin Diftitox

Label: Denileukin Diftitox

NCI Thesaurus Code: C1476 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0717670  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
DAB389 Interleukin-2
DAB389 Interleukin-2 Immunotoxin
Denileukin Diftitox
denileukin diftitox
Interleukin-2 Fusion Protein
Interleukin-2 Fusion Toxin

External Source Codes: 
CAS Registry Number 173146-27-5 (see NLM ChemIDplus info)
NSC Code 714744 (see NCI DTP info)
PDQ Closed Trial Search ID 42325
PDQ Open Trial Search ID 42325 (check for NCI PDQ open clinical trial info)
UMLS CUI C0717670

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For Cutaneous T-cell lymphoma
code C1476
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Denileukin_Diftitox
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom